Search
Pelthos Therapeutics Ord Shs
PTHSAdd to Watchlist
28.660USD
+2.580+9.83%
Close 07-31 16:00（ET）Quotes delayed by 15 min
92.70MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated:Analyst Rating
Based on
7
analysts
Buy
Current Rating
57.714
Target Price
+124.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Pelthos Therapeutics Ord Shs
PTHS
7
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Pelthos Therapeutics Ord Shs's expected revenue for the next quarter?
Pelthos Therapeutics Ord Shs's expected revenue is 15.27M.
What is Pelthos Therapeutics Ord Shs's price target?
Analysts forecast that Pelthos Therapeutics Ord Shs's price target is USD 57.00, with the highest forecast at USD 75.00 and the lowest forecast at USD 50.00.
How have Pelthos Therapeutics Ord ShsPTHS's recent earnings per share performed?
The market expectation was USD -3.09, while Pelthos Therapeutics Ord ShsPTHS's earnings per share (EPS) for the previous quarter was USD -6.81. EPS for the next quarter is expected at USD -3.05.
What is the analyst rating for Pelthos Therapeutics Ord Shs?
Based on the ratings of Pelthos Therapeutics Ord Shs's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.